drugset / Trial / NCT01025453
Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer
Phase 2
Completed
37 enrolled
Memorial Sloan Kettering Cancer Center
National Comprehensive Cancer Network · collabPfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out what effects, good and/or bad, the combination of sorafenib and temsirolimus will have on thyroid cancer. Treatment guidelines from the National Comprehensive Cancer Network include sorafenib as a treatment option for thyroid cancer. Temsirolimus is an intravenous medication that is FDA approved for other type of cancers. In laboratory studies, the addition of temsirolimus to sorafenib works better than sorafenib alone.
Timeline
- Start
- 2009-12-01
- Primary completion
- 2018-01-16
- Completion
- 2018-01-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 200 mg | Oral |
| Subject | Temsirolimus | Small molecule | 25 mg | Intravenous |